KYAT1 and glioma: IFN-γ-mediated KAT-I down-regulation in glioma and the down-regulation of all KATs in glioma compared to HFA may subsequently function to have a reduced capacity to produce the neuroprotective metabolite KYNA at the site of inflammation.